Skip to main content

Aqua Bio Technology ASA: Hydrafacial har inngått samarbeid med Restorsea – Conversion Lab lanserer Veritas MD plattform

Written by Customer Service on . Posted in Public Companies.

Restorseas kommersialisering av Aqua Bio Technologys ASAs klekkeveskeingrediens (Aquabeautine XL) fortsetter.Som nevnt i kommersiell oppdatering 26. november 2020, har Restorsea nylig inngått to lisensavtaler med to partnere i tillegg til lisensavtalen med NASDAQ-noterte Conversion Labs.I forbindelse med Hydrafacial`s fusjon med Vesper Healthcare og den planlagte noteringen på NASDAQ Capital Market (NASDAQ), presenteres Restorsea som ny samarbeidspartner til Hydrafacial fra 2021. Hydrafacial opplyser at selskapet per Q3 2020 har utplassert 15 124 hudpleie maskiner i 87 land.Som nevnt i børsmelding 27 oktober 2020, har Restorsea inngått avtale om lisensiering av Aquabeautine XL til selskapet Conversion Labs som ble notert på NASDAQ 10. desember 2020.  Conversion Lab har i dag offisielt har lanserte sin nye Veritas MD telehelse plattform som nasjonalt vil rulle ut hudpleieserien Nava MD, som baserer seg på Aquabeautine XL.Den positiv trenden fra Restorseas kommersialisering av ABTs proprietære teknologi øker sannsynligheten for at ABT vil motta ytterligere fornyelsesbeløp og økte inntekter fra salg av ingredienser og royalty fra Restorsea og deres lisenstakere.Nærmere opplysninger ved adm. direktør Espen Kvale, telefon 9162 8092.Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.